Versant Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$188K Buy
1,704
+11
+0.6% +$1.06K 0.02% 641
2026
Q2
$133K Buy
1,693
+460
+37% +$31.4K 0.01% 792
2026
Q1
$79.7K Hold
1,233
– – 0.01% 973
2025
Q4
$83K Hold
1,233
– – 0.01% 834
2025
Q3
$90.4K Buy
1,233
+57
+5% +$3.79K 0.01% 755
2025
Q2
$61.2K Buy
1,176
+738
+168% +$42K 0.01% 876
2025
Q1
$27.9K Hold
438
– – ﹤0.01% 1145
2024
Q4
$20.9K Buy
438
+417
+1,986% +$21.4K ﹤0.01% 1012
2024
Q3
$1.2K Hold
21
– – ﹤0.01% 1705
2024
Q2
$1.1K Hold
21
– – ﹤0.01% 1653
2024
Q1
$854 Hold
21
– – ﹤0.01% 1576
2023
Q4
$776 Hold
21
– – ﹤0.01% 1578
2023
Q3
$802 Hold
21
– – ﹤0.01% 1591
2023
Q2
$757 Buy
+21
New +$716 ﹤0.01% 1700

Other funds holding HALO

Versant Capital Management's HALO Position: Q3 2026 in Review

Versant Capital Management increased its Halozyme (HALO) stake by 0.65% in Q3 2026, buying an estimated $1.06K and bringing the position to 1,704 shares worth $188K. The position accounts for 0.02% of the portfolio, ranked #641.

Versant Capital Management first reported a position in HALO in Q2 2023 and has held it in 14 quarters since. 777 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Versant Capital Management held 1,704 shares of Halozyme worth $188K as of Q3 2026.
  • Versant Capital Management bought 11 Halozyme shares in Q3 2026, an estimated $1.06K.
  • Halozyme made up 0.02% of Versant Capital Management's portfolio in Q3 2026, its #641 holding.
  • Versant Capital Management first reported a position in Halozyme in Q2 2023 and has held it in 14 quarters since.
  • 777 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.